|Bid||28.25 x 800|
|Ask||28.34 x 1200|
|Day's Range||27.97 - 29.39|
|52 Week Range||15.58 - 68.65|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.57|
Subscribe to Yahoo Finance Plus to view Fair Value for CSTL
FRIENDSWOOD, Texas, September 23, 2022--Castle announced the publication of a study validating the performance of DecisionDx®-Melanoma’s proprietary algorithm, i31-ROR.
FRIENDSWOOD, Texas, September 21, 2022--Castle provided a proposed framework for use of its MyPath® Melanoma and DiffDx®-Melanoma tests to help achieve personalized management plans.
FRIENDSWOOD, Texas, September 20, 2022--Castle Biosciences will present the Company’s foundational guideposts and three-year financial targets during its Investor Day today.